Table 3.
Blood catecholamine data for healthy adults consuming Capsimax™ and placebo in a randomized cross-over design
| Variable | Pre | 2 hr (pre-ex) |
2.5 hr (1 min post ex) |
4 hr (90 min post ex) |
|---|---|---|---|---|
| Epinephrine (pg·mL-1) Capsimax™ |
41.54 ± 33.56 | 40.09 ± 29.83 | 69.34 ± 43.75 * | 45.36 ± 39.36 |
| Epinephrine (pg·mL-1) Placebo |
37.65 ± 27.16 | 36.54 ± 21.31 | 65.08 ± 51.10 * | 34.49 ± 22.12 |
| Norepinephrine (pg·mL-1) Capsimax™ |
264.90 ± 132.66 | 378.63 ± 210.31** | 491.08 ± 211.54** | 440.10 ± 220.34 ** |
| Norepinephrine (pg·mL-1) Placebo |
242.03 ± 157.63 | 326.84 ± 185.89** | 553.53 ± 200.58** | 344.61 ± 210.45** |
Data are Mean ± SD
No interaction or condition effects were noted for EPI or NE (p > 0.05).
* A time effect was noted for EPI (p < 0.0001); values higher than Pre at 2.5 hr.
** A time effect was noted for NE (p < 0.0001); values higher than Pre at 2 hr, 2.5 hr, and 4 hr.